PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
about
Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis.Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Diseases in Chinese MainlandA prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis
P2860
PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PEG-aspargase and DEP regimen ...... hagocytic lymphohistiocytosis.
@en
PEG-aspargase and DEP regimen ...... hagocytic lymphohistiocytosis.
@nl
type
label
PEG-aspargase and DEP regimen ...... hagocytic lymphohistiocytosis.
@en
PEG-aspargase and DEP regimen ...... hagocytic lymphohistiocytosis.
@nl
prefLabel
PEG-aspargase and DEP regimen ...... hagocytic lymphohistiocytosis.
@en
PEG-aspargase and DEP regimen ...... hagocytic lymphohistiocytosis.
@nl
P2093
P2860
P1476
PEG-aspargase and DEP regimen ...... hagocytic lymphohistiocytosis.
@en
P2093
P2860
P2888
P356
10.1186/S13045-016-0317-7
P577
2016-09-09T00:00:00Z
P6179
1018491619